Compare Vertex Pharmaceuticals Incorporated (VRTX) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs State Street PDR S&P Retail ETF — how do they compare? Vertex Pharmaceuticals Incorporated trades at $478.06 (market cap $121.95B), while State Street PDR S&P Retail ETF trades at $88.47. The key difference: State Street PDR S&P Retail ETF is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals.
| VRTX | XRT | |
|---|---|---|
Market Cap | $121.95B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $529.59 | $90.88 |
52-Week Low | $366.54 | $77.28 |
Enterprise Value | $116.69B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
